Fig 1: Effects of exosomal lncRNA-SOX2OT on osteoclast-related proteins and pathways in a lung cancer BoM model.A Real-time PCR assays for lncRNA-SOX2OT, miR-194-5p, and RAC1 in bone metastatic lesions treated with lncRNA-SOX2OT-knockdown exosomes or lncRNA-SOX2OT-enriched exosomes compared with their respective controls. GAPDH or U6 was used as the internal control. B Real-time PCR analysis for the mRNA levels of TGF-ß, pTHrP, RANKL, and OPG in bone metastatic lesions treated with lncRNA-SOX2OT-knockdown exosomes or lncRNA-SOX2OT-enriched exosomes compared with that in their respective controls. GAPDH was used as the internal control. C, D Western blot analysis for the protein expression levels of TGF-ß, pTHrP, RANKL, and OPG in bone metastatic lesions treated with lncRNA-SOX2OT-knockdown exosomes or lncRNA-SOX2OT-enriched exosomes compared with their respective controls. Beta-actin was used as a referred protein. E, F Western blot analysis for the RAC1 protein in bone metastatic lesions treated with lncRNA-SOX2OT-knockdown or lncRNA-SOX2OT-enriched exosomes compared with that in their respective controls. Beta-actin was used as a referred protein. G Immunohistochemical analysis for the expression of the RAC1 protein in bone metastatic lesions treated with lncRNA-SOX2OT-knockdown or lncRNA-SOX2OT-enriched exosomes compared with that in their respective controls. Black arrows indicate the metastatic foci and cancerous cells in the representative images. Scale bar, 200 µm. Data are representative of three biological replicates, and each experiment was performed at least three times independently. *, P < 0.05; **, P < 0.01 (t test).